Inogen, Inc (INGN) Product Cycle Is More Important Than EBITDA Miss - Needham & Company
Tweet Send to a Friend
Needham & Company analyst, Mike Matson, thinks there is a buying opportunity after Inogen, Inc (NASDAQ: INGN) beat consensus revenue ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
